Tscan Therapeutics Inc Dossier - Source-backed chat

Tscan Therapeutics Inc

TCRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.04

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.31Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $21.3M

Enterprise Value −$46.1M

Shares Outstanding 67.8M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TScan Therapeutics is strategically positioned as a high-potential clinical-stage biotechnology player following its pivotal alignment with the FDA on a registrational path for its lead TCR-T candidate, TSC-101. By executing a major corporate restructuring in late 2025—which included a 30% workforce reduction and the pausing of its solid tumor clinical trials—the company has successfully extended its cash runway into the second half of 2027. This capital discipline allows TScan to focus intensely on its high-probability hematologic malignancy program. The transition to a shorter, 12-day commercial-ready manufacturing process directly addresses previous clinical relapse concerns linked to excessive T-cell expansion, significantly de-risking the upcoming Phase 3 ALLOHA-2 trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.00

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0010%

The Phase 3 trial of TSC-101 experiences enrollment delays or fails to replicate the strong relapse-free survival trends observed in early Phase 1 cohorts. Relapses continue to occur despite the updated 12-day manufacturing process, undermining the therapeutic thesis. With the cash runway expiring in late 2027, the company is forced to execute highly dilutive equity raises at depressed valuations.

Base CaseCentral scenario

$6.0060%

Matches the consensus mean

TScan successfully initiates the Phase 3 trial for TSC-101 and begins Phase 1 trials for follow-on heme candidates TSC-102-A01 and TSC-102-A03. Early data from Cohort C of the ALLOHA trial confirms that the commercial-ready manufacturing process maintains high efficacy and safety. The company manages its cash burn in line with guidance, preserving its runway into H2 2027 while maintaining steady clinical progress.

Bull CaseUpside scenario

$7.0030%

The Phase 3 ALLOHA-2 trial of TSC-101 achieves its primary endpoint of relapse-free survival with superior donor chimerism and zero dose-limiting toxicities, paving the way for accelerated FDA approval. Concurrently, the Amgen collaboration in Crohn's disease achieves early discovery milestones, triggering substantial non-dilutive cash inflows. The newly optimized 12-day manufacturing process proves highly scalable, attracting further big pharma partnerships for in vivo solid tumor engineering.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA alignment on a clear registrational path for lead candidate TSC-101 in AML and MDS.
Strategic pivot and 30% workforce reduction extended the cash runway into the second half of 2027, reducing near-term dilution risk.
Optimized, commercial-ready manufacturing process reduced production time from 17 to 12 days, addressing previous relapse issues.
Strong validation and non-dilutive funding potential through the Amgen collaboration in Crohn's disease, eligible for over $500 million in milestones.

Key Investment Risks

Clinical development risk inherent to early-stage TCR-T cell therapies.
Historical instances of patient relapse or prolonged incomplete chimerism in the Phase 1 study.
Complete reliance on the hematologic program following the pause of the solid tumor clinical pipeline.
Limited cash runway requiring additional capital before commercialization.

Thesis Invalidation Triggers

Failure to initiate the Phase 3 ALLOHA-2 trial of TSC-101 within the projected timeline.
Safety signals, such as severe graft-versus-host disease (GvHD) or dose-limiting toxicities, emerging in the Phase 3 trial.
Data from Cohort C showing high relapse rates or failure to achieve complete donor chimerism.
Termination or negative restructuring of the Amgen collaboration.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.